+44 115 7870500
DevelRx Logo
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact
DevelRx Logo
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact

Scientific Articles - Drug abuse and dependence

Drug Abuse and DependenceADHDBinge-Eating DisorderPsychiatric and Neurological DisordersObesity and Metabolic Disorders

Palandri J, Smith SL, Heal DJ, Wonnacott S, Baily CP. Contrasting effects of the α7 nicotinic receptor antagonist methyllycaconitine in different rat models of heroin reinstatement. J Psychopharmacol, 2021; First Published online March 10th, (https://doi.org/10.1177/0269881121991570).

Smith SL, Dean RL, Todtenkopf MS, Heal DJ. Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats. (https://pubmed.ncbi.nlm.nih.gov/30676189/?from_term=heal+D&from_sort=date&from_pos=5) J Psychopharmacol, 2019; 33: 383-391.

Wright VL, Georgiou P, Bailey A, Heal DJ, Bailey CP, Wonnacott S. Inhibition of α7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine-conditioned place preference and associated changes in AMPA receptor binding. Addict Biol, 2019; 24: 590-603.

Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SL. Psychedelics - Re-opening the doors of perception. (https://pubmed.ncbi.nlm.nih.gov/30144477/?from_term=heal+D&from_sort=date&from_pos=7)  Neuropharmacol, 2018; 142: 1-6.

Heal DJ, Gosden J, Smith SL. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. (https://pubmed.ncbi.nlm.nih.gov/29427652/?from_term=heal+D&from_sort=date&from_pos=9)  Neuropharmacol, 2018; 142: 89-115.

Calderon S, Giarola A, Heal D. Regulatory Framework and Guidance to the Evaluation of the Abuse Liability of Drugs in the United States and Europe. In: Markgraf CG, Hudzik TJ, Compton DR (Eds). Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Academic Press, pp. 245–268, 2015.

Heal DJ, Smith SL, Henningfield JE. CNS stimulants. Neuropharmacol, 2014; 87: 1-3.

Heal DJ, Gosden J, Smith SL. Dopamine reuptake transporter (DAT) "inverse agonism" - A novel hypothesis to explain the enigmatic pharmacology of cocaine. Neuropharmacol, 2014; 87: 19-40.

Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present – A pharmacological and clinical perspective. J Psychopharmacol, 2013; 27: 479-496.

Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil. Neuropharmacol, 2013; 73: 348-58.

Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ. Lisdexamfetamine and immediate-release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacol, 2012; 63: 1064-74.

Kennett A, Heal DJ, Wonnacott S. Pharmacological differences between rat frontal cortex and hippocampus in the nicotinic modulation of noradrenaline release implicate distinct receptor subtypes. Nicotine Tob Res, 2012; 14: 1339-45.

Freeman KB, Heal DJ, McCreary AC, Woolverton WL. Assessment of ropinirole as a reinforcer in rhesus monkeys. Drug Alcohol Depend, 2012; 125: 173-7.

Sidhpura N, Redfern P, Rowley H, Heal D and Wonnacott S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol, 2007; 74: 1292-8.

DevelRx Logo


Pennyfoot Street,





Cookie PolicyPrivacy PolicyTerms & Conditions

Follow us on LinkedIn

Registered in England and Wales

Company number: 12028847